New Cell-Based therapy trial aims to tame rare nerve disease

This early-stage trial tests a new treatment called NouvSoma001 for people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The treatment uses tiny particles from stem cells, given via a spinal injection, to try to control the disease. The study will enroll 69 adults who recently had symptoms and will check for safety and any signs of benefit.